Adcendo ApS has raised an additional €31 million in a Series A financing extension led by Pontifax Venture Capital to support the clinical development of its ADC pipeline, targeting high unmet medical needs in cancer treatments.

Information on the Target

Adcendo ApS is a biotechnology firm based in Copenhagen, Denmark, specializing in the development of innovative antibody-drug conjugates (ADCs) aimed at addressing cancer types with significant unmet medical needs. Recently, the company has successfully raised an additional €31 million through a Series A extension financing round, following a prior €51 million financing completed in April 2021. This latest funding will support the extensive clinical development of its lead ADC asset targeting the uPARAP receptor as well as the advancement of a second ADC pipeline asset.

The uPARAP receptor is characterized by its high expression on the cell surfaces of sarcoma and other mesenchymal cancers, making it a promising target for ADC applications. The unique expression and internalization properties of uPARAP present an attractive opportunity for the development of targeted cancer therapies.

Industry Overview in Denmark

Denmark has emerged as a significant hub for life sciences and biotechnology, driven by a robust healthcare system, substantial investments, and a supportive regulatory environment. The biotech industry in Denmark benefits from a highly ed